Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.
The partners will commercialize Counsyl's Expanded Carrier Screening Test as preconGen, beginning in Spain, Italy, Portugal, Switzerland, and Colombia.
OHSU was granted the rights to offer Biocept's Target Selector liquid biopsy testing services in Oregon as part of the deal.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.
The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.